- Home
- CHRS vs CFBK Comparison
CHRS vs CFBK Comparison
Compare CHRS & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHRS | CFBK |
|---|---|---|
| Founded | 2010 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.0M | 167.9M |
| IPO Year | 2014 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CHRS | CFBK |
|---|---|---|
| Price | $1.43 | $25.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.02 | ★ $29.00 |
| AVG Volume (30 Days) | ★ 973.5K | 74.4K |
| Earning Date | 11-06-2025 | 02-11-2026 |
| Dividend Yield | N/A | ★ 1.25% |
| EPS Growth | N/A | ★ 21.79 |
| EPS | 1.34 | ★ 2.49 |
| Revenue | ★ $277,728,000.00 | $50,724,000.00 |
| Revenue This Year | N/A | $39.98 |
| Revenue Next Year | $67.31 | $10.47 |
| P/E Ratio | ★ $1.02 | $10.26 |
| Revenue Growth | ★ 152.07 | 14.25 |
| 52 Week Low | $0.71 | $19.23 |
| 52 Week High | $1.89 | $27.46 |
Technical Indicators
Market Signals| Indicator | CHRS | CFBK |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 58.53 |
| Support Level | $1.35 | $24.32 |
| Resistance Level | $1.52 | $26.46 |
| Average True Range (ATR) | 0.09 | 0.79 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 58.49 | 37.78 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.